University of Dundee

Molecular Medicine 2010

Allende-Vega, N. and Saville, M. K. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Seminars in cancer biology, 20, 29-39.

Allende-Vega, N., Sparks, A., Lane, D. P. and Saville, M. K. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene, 29, 432-441.

Aoubala, M., Murray-Zmijewski, F., Khoury, M. P., Fernandes, K., Perrier, S., Bernard, H., Prats, A. C., Lane, D. P. and Bourdon, J. C. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell death and differentiation.

Baker, L., Quinlan, P. R., Patten, N., Ashfield, A., Birse-Stewart-Bell, L. J., McCowan, C., Bourdon, J. C., Purdie, C. A., Jordan, L. B., Dewar, J. A., Wu, L. and Thompson, A. M. p53 mutation, deprivation and poor prognosis in primary breast cancer. British journal of cancer, 102, 719-726.

Bergboer, J. G. M., Zeeuwen, P., Irvine, A. D., Weidinger, S., Giardina, E., Novelli, G., Den Heijer, M., Rodriguez, E., Illig, T., Riveira-Munoz, E., Campbell, L. E., Tyson, J., Dannhauser, E. N., O'Regan, G. M., Galli, E., Klopp, N., Koppelman, G. H., Novak, N., Estivill, X., McLean, W. H. I., Postma, D. S., Armour, J. A. L. and Schalkwijk, J. Deletion of Late Cornified Envelope 3B and 3C Genes Is Not Associated with Atopic Dermatitis. Journal of Investigative Dermatology, 130, 2057-2061.

Brown, C. J., Cheok, C. F., Verma, C. S. and Lane, D. P. Reactivation of p53: from peptides to small molecules.

Brown, C. J., Dastidar, S. G., See, H. Y., Coomber, D. W., Ortiz-Lombardia, M., Verma, C. and Lane, D. P. Rational Design and Biophysical Characterization of Thioredoxin-Based Aptamers: Insights into Peptide Grafting. Journal of Molecular Biology, 395, 871-883.

Brown, C. J., Lim, J. J., Leonard, T., Lim, H. C., Chia, C. S., Verma, C. S. and Lane, D. P. Stabilizing the eIF4G1 alpha-Helix Increases Its Binding Affinity with eIF4E: Implications for Peptidomimetic Design Strategies.

Cheok, C., CS, V., J, B. and Lane, D. P. Translating p53 into the clinic.

Cheok, C. F., Kua, N., Kaldis, P. and Lane, D. P. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death and Differentiation, 17, 1486-1500.

Chervet, L., Galichet, A., McLean, W. H. I., Chen, H. J., Suter, M. M., Roosje, P. J. and Muller, E. J. Missing C-terminal filaggrin expression, NFkappaB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis. Experimental Dermatology, 19, E343-E346.

Clericuzio, C., Harutyunyan, K., Jin, W., Erickson, R. P., Irvine, A. D., McLean, W. H., Wen, Y., Bagatell, R., Griffin, T. A., Shwayder, T. A., Plon, S. E., Wang, L. L., Jakasa, I., Koster, E. S., Calkoen, F., McLean, W. H., Campbell, L. E., Bos, J. D., Verberk, M. M., Kezic, S., Smith Fjd Fau - Kaspar, R. L., Kaspar Rl Fau - Schwartz, M. E., Schwartz Me Fau - McLean, W. H. I., McLean Whi Fau - Leachman, S. A. and Leachman, S. A. Identification of a novel C16orf57 mutation in Athabaskan patients with Poikiloderma with Neutropenia

Skin Barrier Function in Healthy Subjects and Patients with Atopic Dermatitis in Relation to Filaggrin Loss-of-Function Mutations

Pachyonychia Congenita BTI - GeneReviews.

Dey, A., Lane, D. P. and Verma, C. S. Modulating the p53 pathway. Seminars in Cancer Biology, 20, 3-9.

Flohr, C., England, K., Radulovic, S., McLean, W. H. I., Campbell, L. E., Barker, J., Perkin, M. and Lack, G. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. British Journal of Dermatology, 163, 1333-1336.

Fu, T., Leachman, S. A., Wilson, N. J., Smith, F. J., Schwartz, M. E. and Tang, J. Y. Genotype-Phenotype Correlations among Pachyonychia Congenita Patients with K16 Mutations.

Fujita, K., Horikawa, I., Mondal, A. M., Jenkins, L. M., Appella, E., Vojtesek, B., Bourdon, J. C., Lane, D. P. and Harris, C. C. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nature cell biology, 12, 1205-1212.

Goh, A., DP, L. and F, G. Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions. Cell Cycle.

Goh, A. M. and Lane, D. P. SNPing Away at Cancer. Cancer Cell, 18, 201-202.

Gruber, R., Janecke, A. R., Grabher, D., Sandilands, A., Fauth, C. and Schmuth, M. Evidence for genetic modifiers other than filaggrin mutations in X-linked ichthyosis. Journal of Dermatological Science, 58, 72-75.

Guo, L., Chua, J., Vijayakumar, D., Lee, K. C., Lim, K., Eng, H., Ghadessy, F., Coomber, D. and Lane, D. P. Detection of the 113p53 protein isoform A p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish. Cell Cycle, 9, 1998-2007.

Hickerson, R. P., Leachman, S. A., Pho, L. N., Gonzalez-Gonzalez, E., Smith, F. J., McLean, W. H., Contag, C. H., Leake, D., Milstone, L. M. and Kaspar, R. L. Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials.

Hudson, T. J., Anderson, W., Aretz, A., Barker, A. D., Bell, C., Bernabe, R. R., Bhan, M. K., Calvo, F., Eerola, I., Gerhard, D. S., Guttmacher, A., Guyer, M., Hemsley, F. M., Jennings, J. L., Kerr, D., Klatt, P., Kolar, P., Kusuda, J., Lane, D. P., Laplace, F., Lu, Y. Y., Nettekoven, G., Ozenberger, B., Peterson, J., Rao, T. S., Remacle, J., Schafer, A. J., Shibata, T., Stratton, M. R., Vockley, J. G., Watanabe, K., Yang, H. M., Yuen, M. M. F., Knoppers, M., Bobrow, M., Cambon-Thomsen, A., Dressler, L. G., Dyke, S. O. M., Joly, Y., Kato, K., Kennedy, K. L., Nicolas, P., Parker, M. J., Rial-Sebbag, E., Romeo-Casabona, C. M., Shaw, K. M., Wallace, S., Wiesner, G. L., Zeps, N., Lichter, P., Biankin, A. V., Chabannon, C., Chin, L., Clement, B., de Alava, E., Degos, F., Ferguson, M. L., Geary, P., Hayes, D. N., Johns, A. L., Nakagawa, H., Penny, R., Piris, M. A., Sarin, R., Scarpa, A., Shibata, T., van de Vijver, M., Futreal, P. A., Aburatani, H., Bayes, M., Bowtell, D. D. L., Campbell, P. J., Estivill, X., Grimmond, S. M., Gut, I., Hirst, M., Lopez-Otin, C., Majumder, P., Marra, M., Nakagawa, H., Ning, Z. M., Puente, X. S., Ruan, Y. J., Shibata, T., Stratton, M. R., Stunnenberg, H. G., Swerdlow, H., Velculescu, V. E., Wilson, R. K., Xue, H. H., Yang, L., Spellman, P. T., Bader, G. D., Boutros, P. C., Campbell, P. J., Flicek, P., Getz, G., Guigo, R., Guo, G. W., Haussler, D., et al. International network of cancer genome projects. Nature, 464, 993-998.

Jakasa, I., Koster, E. S., Calkoen, F., McLean, W. H., Campbell, L. E., Bos, J. D., Verberk, M. M. and Kezic, S. Skin Barrier Function in Healthy Subjects and Patients with Atopic Dermatitis in Relation to Filaggrin Loss-of-Function Mutations.

Joseph, T. L., Madhumalar, A., Brown, C. J., Lane, D. P. and Verma, C. Differential binding of p53 and nutlin to MDM2 and MDMX Computational studies. Cell Cycle, 9, 1167-1181.

Joseph, T. L., P, L. D. and Verma, C. S. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.

Judge, M., McLean, W. and Munro, C. (2010) Disorders of keratinization. In Textbook of Dermatology(Ed, Rook) Blackwell Publishing, Oxford, pp. 19.11 - 19.122.

Khoury, M. P. and Bourdon, J. C. The isoforms of the p53 protein. Cold Spring Harbor perspectives in biology, 2, a000927.

Lane, D. P., Cheok, C. F., Brown, C., Madhumalar, A., Ghadessy, F. J. and Verma, C. Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle, 9, 540-547.

Lane, D. P., Cheok, C. F., Brown, C. J., Madhumalar, A., Ghadessy, F. J. and Verma, C. The Mdm2 and p53 genes are conserved in the Arachnids. Cell Cycle, 9, 748-754.

Lane, D. P., Cheok, C. F. and Lain, S. p53-based Cancer Therapy. Cold Spring Harbor Perspectives in Biology, 2.

Lane, D. P. and Levine, A. p53 Research: the past thirty years and the next thirty years.

Lane, D. P., Verma, C. and Fang, C. C. The p53 inducing drug dosage may determine quiescence or senescence.

Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J. D., McLean, W. H. I., Milstone, L. M. and Kaspar, R. L. First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Molecular Therapy, 18, 442-446.

Lemée, F., Bergoglio, V., Fernandez-Vidal, A., Machado-Silva, A., Pillaire, M. J., Bieth, A., Gentil, C., Baker, L., Martin, A. L., Leduc, C., Lam, E., Magdeleine, E., Filleron, T., Oumouhou, N., Kaina, B., Seki, M., Grimal, F., Lacroix-Triki, M., Thompson, A., Roché, H., Bourdon, J. C., Wood, R. D., Hoffmann, J. S. and Cazaux, C. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proceedings of the National Academy of Sciences of the United States of America, 107, 13390-13395.

Leslie Pedrioli, D. M., Karpanen, T., Dabouras, V., Jurisic, G., van de Hoek, G., Shin, J. W., Marino, D., Kalin, R. E., Leidel, S., Cinelli, P., Schulte-Merker, S. and Branli, A. W. (2010) miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo. Molecular and Cellular Biology, 30, 3620-3634.

Machado-Silva, A., Perrier, S. and Bourdon, J. C. p53 family members in cancer diagnosis and treatment. Seminars in cancer biology, 20, 57-62.

Marcel, V., Olivier, M., Mollereau, B., Hainaut, P. and Bourdon, J. C. First International p53 Isoforms Meeting: 'p53 isoforms through evolution: from identification to biological function'. Cell death and differentiation.

Marcel, V., Perrier, S., Aoubala, M., Ageorges, S., Groves, M. J., Diot, A., Fernandes, K., Tauro, S. and Bourdon, J. C. Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS letters, 584, 4463-4468.

Mavinahalli, J. N., Madhumalar, A., Beuerman, R. W., Lane, D. P. and Verma, C. Differences in the transactivation domains of p53 family members: a computational study. Bmc Genomics, 11.

McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon, J. C., Perkins, N., Fuller-Pace, F. and Meek, D. W. p53-dependent repression of polo-like kinase-1 (PLK1). Cell cycle (Georgetown, Tex.), 9, 4200-4212.

McLean, W. H. I. The Allergy Gene. Scientist, 24, 34-39.

Moore, H. C., Jordan, L. B., Bray, S. E., Baker, L., Quinlan, P. R., Purdie, C. A., Thompson, A. M., Bourdon, J. C. and Fuller-Pace, F. V. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer. Oncogene, 29, 6475-6484.

Nomura, Y., Akiyama, M., Nomura, T., Nemoto-Hasebe, I., Abe, R., McLean, W. H. I. and Shimizu, H. Chromosome 11q13.5 variant: No association with atopic eczema in the Japanese population. Journal of Dermatological Science, 59, 210-212.

O'Regan, G. M., Campbell, L. E., Cordell, H. J., Irvine, A. D., McLean, W. H. I. and Brown, S. J. Chromosome 11q13.5 variant associated with childhood eczema: An effect supplementary to filaggrin mutations. Journal of Allergy and Clinical Immunology, 125, 170-174.

O'Regan, G. M., Kemperman, P. M. J. H., Sandilands, A., Chen, H., Campbell, L. E., Kroboth, K., Watson, R., Rowland, M., Puppels, G. J., McLean, W. H. I., Caspers, P. J. and Irvine, A. D. Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes. Journal of Allergy and Clinical Immunology, 126, 574.

Osawa, R., Konno, S., Akiyama, M., Nemoto-Hasebe, I., Nomura, T., Nomura, Y., Abe, R., Sandilands, A., McLean, W. H. I., Hizawa, N., Nishimura, M. and Shimizu, H. Japanese-Specific Filaggrin Gene Mutations in Japanese Patients Suffering from Atopic Eczema and Asthma. Journal of Investigative Dermatology, 130, 2834-2836.

See, H. Y. and Lane, D. P. A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides. Journal of Molecular Biology.

Smith, F., Kaspar, R., Schwartz, M. E., McLean, W. H. and Leachman, S. A. Pachyonychia Congenita. Gene Reviews.

Stevenson, D. J., Gunn-Moore, F. J., Campbell, P. and Dholakia, K. Single cell optical transfection. Journal of the Royal Society Interface, 7, 863-871.

Strange, A., Capon, F., Spencer, C. C. A., Knight, J., Weale, M. E., Allen, M. H., Barton, A., Band, G., Bellenguez, C., Bergboer, J. G. M., Blackwell, J. M., Bramon, E., Bumpstead, S. J., Casas, J. P., Cork, M. J., Corvin, A., Deloukas, P., Dilthey, A., Duncanson, A., Edkins, S., Estivill, X., Fitzgerald, O., Freeman, C., Giardina, E., Gray, E., Hofer, A., Huffmeier, U., Hunt, S. E., Irvine, A. D., Jankowski, J., Kirby, B., Langford, C., Lascorz, J., Leman, J., Leslie, S., Mallbris, L., Markus, H. S., Mathew, C. G., McLean, W. H. I., McManus, R., Mossner, R., Moutsianas, L., Naluai, A. T., Nestle, F. O., Novelli, G., Onoufriadis, A., Palmer, C. N. A., Perricone, C., Pirinen, M., Plomin, R., Potter, S. C., Pujol, R. M., Rautanen, A., Riveira-Munoz, E., Ryan, A. W., Salmhofer, W., Samuelsson, L., Sawcer, S. J., Schalkwijk, J., Smith, C. H., Stahle, M., Su, Z., Tazi-Ahnini, R., Traupe, H., Viswanathan, A. C., Warren, R. B., Weger, W., Wolk, K., Wood, N., Worthington, J., Young, H. S., Zeeuwen, P., Hayday, A., Burden, A. D., Griffiths, C. E. M., Kere, J., Reis, A., McVean, G., Evans, D. M., Brown, M. A., Barker, J. N., Peltonen, L., Donnelly, P., Trembath, R. C., Genetic Anal Psoriasis, C. and Wellcome Trust Case, C. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nature Genetics, 42, 985-U106.

Thompson, A. M. and Lane, D. P. p53 transcriptional pathways in breast cancer: the good, the bad and the complex. Journal of Pathology, 220, 401-403.

Wang, S. D., Griffiths, G., Midgley, C. A., Barnett, A. L., Cooper, M., Grabarek, J., Ingram, L., Jackson, W., Kontopidis, G., McClue, S. J., McInnes, C., McLachlan, J., Meades, C., Mezna, M., Stuart, I., Thomas, M. P., Zheleva, D. I., Lane, D. P., Jackson, R. C., Glover, D. M., Blake, D. G. and Fischer, P. M. Discovery and Characterization of 2-Anilino-4-(Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents. Chemistry & Biology, 17, 1111-1121.

Wang, S. D., Midgley, C. A., Scaerou, F., Grabarek, J. B., Griffiths, G., Jackson, W., Kontopidis, G., McClue, S. J., McInnes, C., Meades, C., Mezna, M., Plater, A., Stuart, I., Thomas, M. P., Wood, G., Clarke, R. G., Blake, D. G., Zheleva, D. I., Lane, D. P., Jackson, R. C., Glover, D. M. and Fischer, P. M. Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors. Journal of Medicinal Chemistry, 53, 4367-4378.